![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
AM Andrews, B Ladenheim, CJ Epstein, JL Cadet and DL Murphy
Laboratory of Clinical Science, National Institute of Mental Health, Bethesda, Maryland 20892, USA. ama@helix.nih.gov
Administration of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) analog 1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine (2'-NH2-MPTP; 4 x 15 mg/kg) to CD-1 mice was found to cause substantial decreases in cortical and hippocampal 5-hydroxytryptamine (5-HT) and norepinephrine (NE) to 20-30% of control 3 weeks after treatment. The magnitude of these depletions was similar to those reported previously in Swiss Webster and C57BL/6 mice given 4 x 20 mg/kg 2'-NH2-MPTP, and in keeping with these prior studies, striatal dopamine levels were unchanged by 2'-NH2-MPTP treatment in CD-1 mice. Subsequently, transgenic CD-1 mice producing high levels of human cytosolic Cu-Zn superoxide dismutase (SOD) were studied to assess the role of oxygen radicals in the mechanism of action of 2'-NH2-MPTP. In contrast to the results described above, 5-HT and NE levels were almost completely unaffected by 2'-NH2-MPTP treatment in homozygous SOD mice bearing 5- fold increases in brain SOD activity. In 2'-NH2-MPTP-treated heterozygous SOD mice, which showed an average 3-fold increase in brain SOD activity, only moderate depletions in cortical and hippocampal 5-HT (50-60% of control) and NE (30-40% of control) were observed. Additionally, the density of [125I]RTI-55-labeled 5-HT uptake sites was studied to further assess possible 5-HT terminal loss. In various cortical and hippocampal subregions of nontransgenic mice, 5-HT uptake sites were reduced to 20-35% of control after 2'-NH2-MPTP treatment, in comparison with homozygous SOD mice, which were affected only minimally by 2'-NH2-MPTP administration, and heterozygous SOD mice, which showed intermediate reductions in 5-HT uptake site density on the order of 55- 80% of control. Together, these data indicate that mice genetically endowed with increased SOD activity are protected from 2'-NH2-MPTP- induced toxicity, thereby implicating superoxide radicals in the mechanism of action of a neurotoxin that selectively depletes 5-HT and NE without affecting dopamine.
This article has been cited by other articles:
|
|
 |
|
  T. Andoh, P. B. Chock, D. L. Murphy, and C. C. Chiueh Role of the Redox Protein Thioredoxin in Cytoprotective Mechanism Evoked by (-)-Deprenyl Mol. Pharmacol., November 1, 2005; 68(5): 1408 - 1414. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Numis, E. L. Unger, D. L. Sheridan, A. C. Chisnell, and A. M. Andrews The Role of Membrane and Vesicular Monoamine Transporters in the Neurotoxic and Hypothermic Effects of 1-Methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine (2'-NH2-MPTP) Mol. Pharmacol., September 1, 2004; 66(3): 718 - 727. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. Luellen, D. B. Miller, A. C. Chisnell, D. L. Murphy, J. P. O'Callaghan, and A. M. Andrews Neuronal and Astroglial Responses to the Serotonin and Norepinephrine Neurotoxin: 1-Methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 923 - 931. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Unger, P. Mazzola-Pomietto, D. L. Murphy, and A. M. Andrews 2'-NH2-MPTP [1-Methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine] Depletes Serotonin and Norepinephrine in Rats: A Comparison with 2'-CH3-MPTP [1-Methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine] J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 527 - 533. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Donovan, L. A. Mamounas, A. M. Andrews, M. E. Blue, and J. S. McCasland GAP-43 Is Critical for Normal Development of the Serotonergic Innervation in Forebrain J. Neurosci., May 1, 2002; 22(9): 3543 - 3552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Ladenheim, I. N. Krasnova, X. Deng, J. M. Oyler, A. Polettini, T. H. Moran, M. A. Huestis, and J. L. Cadet Methamphetamine-Induced Neurotoxicity Is Attenuated in Transgenic Mice with a Null Mutation for Interleukin-6 Mol. Pharmacol., April 13, 2001; 58(6): 1247 - 1256. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. S. Goldstein, C. Holmes, S.-T. Li, S. Bruce, L. V. Metman, and R. O. Cannon III Cardiac Sympathetic Denervation in Parkinson Disease Ann Intern Med, September 5, 2000; 133(5): 338 - 347. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
